Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $737.1 million.

  • Ocular Therapeutix's Cash & Equivalents rose 8797.66% to $737.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $737.1 million, marking a year-over-year increase of 8797.66%. This contributed to the annual value of $737.1 million for FY2025, which is 8797.66% up from last year.
  • Ocular Therapeutix's Cash & Equivalents amounted to $737.1 million in Q4 2025, which was up 8797.66% from $344.8 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Cash & Equivalents peaked at $737.1 million during Q4 2025, and registered a low of $66.6 million during Q2 2023.
  • For the 5-year period, Ocular Therapeutix's Cash & Equivalents averaged around $264.2 million, with its median value being $193.8 million (2021).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 5049.32% in 2023, then skyrocketed by 59016.3% in 2024.
  • Ocular Therapeutix's Cash & Equivalents (Quarter) stood at $164.2 million in 2021, then crashed by 37.68% to $102.3 million in 2022, then surged by 91.4% to $195.8 million in 2023, then surged by 100.25% to $392.1 million in 2024, then soared by 87.98% to $737.1 million in 2025.
  • Its Cash & Equivalents was $737.1 million in Q4 2025, compared to $344.8 million in Q3 2025 and $391.1 million in Q2 2025.